The Runners Who Never Saw the Finish

The first pan-RAS drug just won FDA approval after forty years of failure. What does it mean to own work whose payoff and credit go to someone else?

Share

Eighteen of the twenty genes came back normal. That, according to a 2021 account in the Guardian, is what Channing Der found in the early 1980s as a young researcher in Geoffrey Cooper's lab at Harvard Medical School, testing candidates to see which were altered in cancer cells. The two that weren't were RAS genes. Cooper's reaction, as he later recalled it: "This could be one of the most significant discoveries in cancer biology in decades."

He was right, and it took far longer than anyone expected to matter for patients. Last Wednesday the FDA approved daraxonrasib, a once-daily pill from Revolution Medicines, for adults with metastatic pancreatic cancer that has progressed after earlier treatment. In the phase 3 trial, median survival was 13.2 months on the drug against 6.7 months on chemotherapy. According to the American Association for Cancer Research, it is the first pan-RAS inhibitor approved for any cancer, in a disease where more than 90% of tumors carry KRAS mutations.

The approval matters for patients first. The part of the story that interests me here is the forty years between Der's bench and this week, and the people who spent much of their working lives in that gap.

The history is not flattering to anyone who likes clean stories about effort and reward. In the early 1990s, drugs that blocked an enzyme called farnesyltransferase stopped RAS-driven tumors growing in mice, and large pharmaceutical companies funded human trials. One after another the drugs failed, because cancer cells had a backup route around the block. Der told the Guardian that "people certainly became disillusioned." An Amgen research chief, David Reese, called the protein "the Death Star": its surface was smooth, and molecules simply slid off.

Some people kept going anyway. The cancer biologist Frank McCormick began urging the chemist Kevan Shokat in 1999 to find a way to drug KRAS. "Even though I told him I couldn't think of a way to do that, he kept encouraging me," Shokat recalled. In 2013 his team found a molecule that bound a pocket on a mutant form of the protein that, in his words, "no one had ever seen." That work led to sotorasib, approved in 2021 for a subset of lung cancers, and daraxonrasib, though it works differently, stands on the same pile of knowledge, including everything learned from what failed.

Shokat has said that finished accounts of science tend to leave out "all the dead ends and cliffs you avoided," and he once estimated that "easily 2,000 scientists around the world" were working on the problem. Most of them will never be named in a story like this one. Some spent careers on approaches that went nowhere. Some retired before 2013. Some, presumably, were the people whose failed trials told everyone else where not to look.

That is what I find hardest and most clarifying about this story. A lot of advice about owning your life assumes that ownership and credit travel together: you do the work, you get the result, your name goes on it. Science on hard problems works more like a relay in which most runners never see the finish. If you measure a career by whether you personally delivered the breakthrough, most of these careers were failures. If you measure it by whether the field moved because you ran your leg properly, many of them were essential.

I'm drawn to the second measure. There's an old idea in East Asian thought that you do everything humanly possible and then leave the outcome to heaven. Far from resignation, it is a refusal to let your effort be held hostage by a result you don't control. The people who mapped RAS's dead ends seem to me a clean example of it, and also of something more generous: handing what you learned to people you will never meet, so that they don't have to pay the same price.

That framing, though, is much easier to admire from outside. Telling a researcher ten years into a program with nothing publishable that their failures are a gift to the future can sound like a consolation prize designed by people who got the prize. Grant systems, hiring committees and drug company valuations mostly reward the finish, not the leg. If a culture praises unglamorous persistence in speeches while funding only winners, the speeches are not worth much. And the financial upside of this approval will flow to a company and its shareholders, which is how the system is built, while many of the people who made it possible worked on salaries in public labs.

I don't want to wrap this in a lesson about patience, because most of the people who were patient were never rewarded for it. What I would ask anyone who admires the relay, myself included, is harder: if you knew today that your best years of work would end as someone else's footnote, what would you need from the people around you to keep running your leg anyway?

— The Andes